Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells

Prostate

Volumn 71, Issue 12, 2011, Pages 1299-1308

  Rajabi, Hasan ^a   Joshi, Maya Datt ^a   Jin, Caining ^a   Ahmad, Rehan ^a   Kufe, Donald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

androgen receptor; androgen dependence; miR 125b; MUC1; prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; MICRORNA; MICRORNA 125B; MUCIN 1; MUCIN 1C; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LNCAP; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANDROGENS; ANTISENSE ELEMENTS (GENETICS); BINDING SITES; CELL LINE, TUMOR; CONSENSUS SEQUENCE; DOWN-REGULATION; HUMANS; MALE; MICRORNAS; MUCIN-1; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 79960747380     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21344     Document Type: Article

References (49)

1. Kufe D,. Mucins in cancer: Function, prognosis and therapy. Nature Reviews Cancer 2009; 9: 874-885.
2. Ahmad R, Raina D, Joshi MD, Kawano T, Kharbanda S, Kufe D,. MUC1-C oncoprotein functions as a direct activator of the NF-kappaB p65 transcription factor. Cancer Res 2009; 69: 7013-7021.
3. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, McClary C, Joshi MD, MacDermed D, Weichselbaum R, Kufe D,. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene 2010; 29 (6): 920-929.
4. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D,. MUC1 oncoprotein blocks GSK3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005; 65: 10413-10422. (Pubitemid 41743735)
5. Wei X, Xu H, Kufe D,. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005; 7: 167-178. (Pubitemid 40248342)
6. Khodarev N, Pitroda S, Beckett M, MacDermed D, Huang L, Kufe D, Weichselbaum R,. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res 2009; 69: 2833-2837.
7. Pitroda S, Khodarev N, Beckett M, Kufe D, Weichselbaum R,. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci USA 2009; 106: 5837-5841.
8. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW, Weichselbaum R,. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 2010; 3: 16.
9. Li Y, Liu D, Chen D, Kharbanda S, Kufe D,. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 2003; 22: 6107-6110. (Pubitemid 37175889)
10. Sachdeva M, Mo YY,. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70 (1): 378-387.
11. Rajabi H, Jin C, Ahmad R, McClary C, Kufe D,. Mucin 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes Cancer 2010; 1 (1): 62-65.
12. Jin C, Rajabi H, Kufe D,. miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. Int J Oncol 2010; 37 (1): 61-69.
13. Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC,. MUC1 expression in prostate carcinoma: Correlation with grade and stage. Mol Urol 1999; 3 (3): 163-168.
14. Cozzi PJ, Wang J, Delprado W, Perkins AC, Allen BJ, Russell PJ, Li Y,. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis 2005; 22 (7): 565-573. (Pubitemid 43234641)
15. Arai T, Fujita K, Fujime M, Irimura T,. Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis. Int J Urol 2005; 12 (7): 654-661. (Pubitemid 41725491)
16. Andrén O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, Mucci LA,. MUC-1 gene is associated with prostate cancer death: A 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007; 97 (6): 730-734. (Pubitemid 47396290)
17. Garbar C, Mascaux C, Wespes E,. Expression of MUC1 and sialyl-Tn in benign prostatic glands, high-grade prostate intraepithelial neoplasia and malignant prostatic glands: A preliminary study. Anal Quant Cytol Histol 2008; 30 (2): 71-77. (Pubitemid 351501866)
18. Rabiau N, Dechelotte P, Guy L, Satih S, Bosviel R, Fontana L, Kemeny JL, Boiteux JP, Bignon YJ, Bernard-Gallon D,. Immunohistochemical staining of mucin 1 in prostate tissues. In Vivo 2009; 23 (2): 203-207.
19. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR,. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101 (3): 811-816. (Pubitemid 38121040)
20. Scher HI, Sawyers CL,. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23 (32): 8253-8261. (Pubitemid 46211563)
21. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45. (Pubitemid 33741879)
22. Taplin ME, Balk SP,. Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91 (3): 483-490.
23. Joshi MD, Ahmad R, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D,. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther 2009; 8: 3056-3065.
24. Cha T, Qiu L, Chen C, Wen Y, Hung M,. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 2005; 65 (6): 2257-2295.
25. Ren J, Agata N, Chen D, Li Y, Yu W-H, Huang L, Raina D, Chen W, Kharbanda S, Kufe D,. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents. Cancer Cell 2004; 5: 163-175. (Pubitemid 38283802)
26. Wang Q, Carroll JS, Brown M,. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 2005; 19 (5): 631-642. (Pubitemid 41219439)
27. Yin L, Kufe D,. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003; 278 (37): 35458-35464. (Pubitemid 37102316)
28. Wei X, Xu H, Kufe D,. MUC1 oncoprotein stabilizes and activates estrogen receptor α. Mol Cell 2006; 21 (2): 295-305. (Pubitemid 43099944)
29. Navone N, Olive M, Ozen M, Davis R, Troncoso P, Tu S, Johnston D, Pollack A, Pathak S, von Eschenbach A, Logothetis C,. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997; 3 (12 Pt 1): 2493-2500. (Pubitemid 28133173)
30. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ,. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62 (22): 6606-6614. (Pubitemid 35364127)
31. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW,. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104 (50): 19983-19988.
32. Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J,. A STAT-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. J Biol Chem 2001; 276 (9): 6191-6199.
33. Suh J, Rabson AB,. NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon ? J Cell Biochem 2004; 91 (1): 100-117.
34. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ,. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68 (16): 6762-6769.
35. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD,. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18 (51): 7389-7394. (Pubitemid 30032121)
36. Parrondo R, de las Pozas A, Reiner T, Rai P, Perez-Stable C,. NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol Cancer 2010; 9: 182.
37. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R,. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62 (22): 6659-6666. (Pubitemid 35364135)
38. Ueda T, Bruchovsky N, Sadar MD,. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277 (9): 7076-7085. (Pubitemid 34959964)
39. Burd CJ, Morey LM, Knudsen KE,. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 2006; 13 (4): 979-994. (Pubitemid 46212560)
40. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW,. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2010 [Epub ahead of print].
41. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM,. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65 (16): 7065-7070. (Pubitemid 41161233)
42. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C,. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006; 5: 24.
43. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA,. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8 (10): R214.
44. Chen Y, Sawyers C, Scher H,. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8 (4): 440-448.
45. Gasparian A, Yao Y, D K, Lyakh L, Karseladze A, Slaga T, Budunova I,. The role of IKK in constitutive activation of NF-ÎB transcription factor in prostate carcinoma cells. J Cell Sci 2002; 115 (Pt 1): 141-151. (Pubitemid 34105537)
46. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S, Kufe D,. MUC1 oncoprotein activates the I|B kinase β complex and constitutive NF-|B signaling. Nat Cell Biol 2007; 9: 1419-1427. (Pubitemid 350201755)
47. Wang G, Wang J, Sadar MD,. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008; 68 (23): 9918-9927.
48. Truica CI, Byers S, Gelmann EP,. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000; 60 (17): 4709-4713.
49. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z,. Linking beta-catenin to androgen-signaling pathway. J Biol Chem 2002; 277 (13): 11336-11344.